Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32

Guggenheim analyst Subbu Nambi has maintained a 'Buy' rating on Adaptive Biotechnologies (NASDAQ: ADPT) and increased the price target from $25 to $32.